Study links hyperinflammatory monocytes to FIRES Share Doximity Facebook LinkedIn Twitter Print details July 21, 2023 Cryptogenic drug-resistant seizure disorders may involve inflammatory processes that traditional anti-seizure medications don't target. Mayo Clinic researchers found that febrile infection-related epilepsy syndrome (FIRES) might be associated with hyperinflammatory monocytic responses to normally banal bacterial pathogens. The researchers isolated peripheral blood mononuclear cells (PBMCs) from blood drawn from a 9-year-old child with FIRES both before and after successful treatment with intrathecal dexamethasone. As described in a case report published in the May 2023 issue of Annals of Clinical and Translational Neurology, the previously healthy boy had presented with seizures following streptococcal pharyngitis. The PBMCs were stimulated ex vivo with bacterial or viral ligands. Cytokine release from the stimulated cells and the levels of inflammatory factors in blood and cerebrospinal fluid were measured and compared with those of healthy pediatric controls. Key findings تمييز النمط الظاهري للاستجابة الالتهابية المفرطة تكبير الصورة قريب تمييز النمط الظاهري للاستجابة الالتهابية المفرطة تمييز النمط الظاهري للاستجابة الالتهابية المفرطة عُزلت خلايا الدم المحيطي وحيدة النواة من دم المريض بأكمله قبل العلاج باستخدام ديكساميثازون داخل القِراب، وكذلك بعد العلاج وتوقف النوبات المقاومة للعلاج. على الجهة اليسرى، أظهر تحليل قياس التدفق الخلوي وعملية فرز الخلايا CD14+CD16+ أن العلاج ساهم في تقليل عدد الوحيدات الالتهابية هذه. وكما هو موضح على الجانب الأيمن العلوي، أظهر قياس السيتوكينات الالتهابية، مثل الإنترلوكين 6 (IL6) و CXCL8، في مصل الدم عودة هذه العوامل إلى مستوياتها الطبيعية بعد العلاج. وفي الجهة السفلية اليمنى، أدى التحفيز خارج الجسم باستخدام منتجات بكتيرية إلى استجابة التهابية مفرطة في خلايا الدم المحيطي وحيدة النواة المعزولة قبل العلاج، والتي عادت إلى مستوياتها الطبيعية بعد بدء العلاج. The patient's blood and cerebral spinal fluid had high levels of inflammatory factors despite treatment with conventional therapies, including intravenous immune globulin, plasma exchange, systemic methylprednisolone and anakinra. Ex vivo stimulation of the patient's PBMCs revealed exaggerated interleukin-6 and CXCL8 release in response to bacterial exposure. The hyperinflammatory phenotype resolved after the initiation of intrathecal dexamethasone, with the patient experiencing profound recovery. The researchers note that the mechanism by which dexamethasone mediated these effects is unclear. "It may be that the locus of corticosteroid delivery matters more than the specific identity of the drug," says Charles L. Howe, Ph.D., director of the Translational Neuroimmunology Laboratory at Mayo Clinic in Rochester, Minnesota. While more research is needed, the Mayo Clinic study offers potential guidance for clinicians managing individuals with FIRES. "There may be diagnostic relevance in profiling the ex vivo responses of innate immune cells, in addition to performing rapid, serial profiling of inflammatory factors in serum and cerebral spinal fluid," Dr. Howe says. For more informationHowe CL, et al. Drug-resistant seizures associated with hyperinflammatory monocytes in FIRES. Annals of Clinical and Translational Neurology. 2023;10:719. Translational Neuroimmunology Laboratory. Mayo Clinic. Refer a patient to Mayo Clinic. MAC-20550764 المتخصصون في المجالات الطبية Study links hyperinflammatory monocytes to FIRES